A university of Houston pharmaceutical scientist is developing a drug which could bring relief to children suffering with Familial Adenomatous Polyposis (FAP), a rare genetic disorder characterized by hundreds if not thousands of colorectal polyps. This hereditary cancer predisposition syndrome occurs in 3 per 100000 live births and, if left untreated, causes colorectal cancer in patients nearly 100 percent of the time. Prior medication for the diseases failed because it increased the risk of heart attacks and death.